LEADER 01448nam  2200433   450 
001 9910707393603321
005 20160707082328.0
035   $a(CKB)5470000002463578
035   $a(OCoLC)953172949
035   $a(OCoLC)995470000002463578
035   $a(EXLCZ)995470000002463578
100   $a20160707d1998      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 14$aThe impact of high-priced generic drugs on Medicare and Medicaid
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d1998.
215   $a1 online resource (26 unnumbered pages) $cillustrations
300   $aTitle from title screen (viewed July 1, 2016).
300   $a"July 1998."
300   $a"OEI-03-97-00510."
606   $aMedicare$xCosts
606   $aMedicaid$xCosts
606   $aGeneric drugs$xPrices$zUnited States
606   $aPharmaceutical services insurance$zUnited States
606   $aPharmaceutical policy$zUnited States
615  0$aMedicare$xCosts.
615  0$aMedicaid$xCosts.
615  0$aGeneric drugs$xPrices
615  0$aPharmaceutical services insurance
615  0$aPharmaceutical policy
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707393603321
996   $aThe impact of high-priced generic drugs on Medicare and Medicaid$93492815
997   $aUNINA